We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Accuracy of Point-of-Care Tests for Syphilis Analyzed

By LabMedica International staff writers
Posted on 12 Mar 2013
Syphilis is on the rise worldwide and there is an urgent need for reliable and rapid screening, particularly for people who live in areas where access to health care is limited. More...


A major change in approach to syphilis testing has been called for which recommends replacing first-line laboratory tests with point-of-care tests (POC) tests globally, especially in resource-limited settings.

An international team, led by scientists at McGill University Health Center (Montreal, QC, Canada) has demonstrated that rapid POC tests for syphilis are as accurate as conventional laboratory tests. Currently, syphilis is screened using conventional laboratory-based tests that can take up to three weeks to deliver results. These tests require chemical agents, trained staff, and a continuous supply of electricity, which are not readily available in some parts of the world. Rapid and POC tests can be performed on a simple finger stick sample one patient at a time, and the results communicated to the patient within 20 minutes, saving time and helping doctors order confirmatory tests and rapidly flagging patients who need treatment.

The team identified 18 rapid and POC tests in global use in a meta-analysis. The vast majority were immunochromatographic strip (ICS) based assays with most tests being Determine (Abbott Diagnostics; Maidenhead, UK) at 29% (38/131); SD Biolines (Standard Diagnostics; Seoul, South Korea) at 18% (23/131); VisiTect (Omega Diagnostics; Alva, UK) at 16% (21/131); and Syphicheck (Qualpro; Goa, India) at 15% (19/131). In whole blood sample, using a Treponema pallidum (TP) specific reference standard, under the imperfect reference standard assumption, sensitivity and specificity estimates for Determine was 86.3% and 95.9%; for SD Bioline was 84.5% and 98.0%; for Syphicheck was 74.5% and 99.6%; and for VisiTect was 74.3% and 99.4%.

Nitika Pant Pai, MD, MPH, PhD, a lead author of the study said, “Our study has major worldwide implications for populations living in rural areas with limited access to healthcare. These tests offer the potential to expedite first line screening in settings where people have no access to a primary care physician or where laboratories take more than a week to deliver results." The study was published on February 26, 2013, in the journal Public Library of Science ONE.

Related Links:

McGill University Health Center
Abbott Diagnostics
Standard Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.